Bladder/Kidney/Other Urologic Cancers
"These results indicate that nicotine nitrosation occurs in vivo in mice and that e-cigarette smoke is carcinogenic to the murine lung and bladder and harmful to the murine heart," the authors write.
Across studies, the pooled sensitivity of MR imaging was 0.90 and the specificity was 0.88 for differentiating tumors staged T1 or lower from those staged T2 or higher.
Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma.
"If [the sNDA is] approved, Cabometyx will offer an important new alternative for the treatment of patients with previously untreated advanced RCC," said Michael M. Morrissey, PhD, President and CEO of Exelixis.
In the United States, Canada, and United Kingdom, physicians do not have the legal duty to assist unless there is a prior patient-physician relationship.
The greatest incidence of bladder cancer was among the group who initiated pioglitazone treatment, in which there were 308 cases per 100,000 person-years.
In the per-protocol analysis, the researchers found that the average survival after surgery for those receiving capecitabine was 53 months, compared to 36 months for those who only had surgery. Existing Treatment Should be Considered Standard of Care in Biliary Cancer
In addition, the FDA has granted accelerated approval for use in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
Safety and efficacy of Bavenico was evaluated in the JAVELIN study that included 242 patients who were followed for a minimum of both 13 weeks and 6 months at the time of data cut-off.
The confirmed ORR was 26.3% in patients with a high PD-L1 score (n=95) and 4.1% in patients with a low or negative PD-L1 score (n=73).
Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.
A trial involving 573 patients with HCC whose tumors progressed after receiving sorafenib demonstrated the safety and efficacy of Stivarga in this population.
Prior to this, Tecentriq was approved for use in locally advanced or mUC in patients with disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before or after surgery.
The FDA has accepted and granted Priority Review to the Biologics License Application (BLA) for avelumab (Merck and Pfizer) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy.
Outreach strategies increase the percentage of patients with cirrhosis who undergo hepatocellular carcinoma (HCC) screening.
The FDA has approved Opdivo (nivolumab; Bristol-Myers Squibb) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-based chemotherapy or for those who have disease progression within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy.
For men with bladder cancer, androgen suppression therapy may be prophylactic for intravesical recurrence, according to a study published in the February issue of The Journal of Urology.
Prolonged work-related stress in men has been tied to increased chances of cancer at five sites; lung, colon, rectal, stomach and lymphatic.
Genentech announced that the Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab)
Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for arginine synthesis, occurs in invasive bladder cancer, according to a study published online in The American Journal of Pathology.
Healthcare professionals should not use the drug in patients with active bladder cancer and should carefully consider the risks and benefits prior to using it in patients with a history of bladder cancer.
A single moderate-dose of psilocybin (a hallucinogenic compound contained in psychedelic mushrooms) was found to produce enduring anxiolytic and antidepressant effects in distressed cancer patients with life-threatening diagnoses.
The experimental drug CB-839 shows promise in treating kidney cancer, according to research presented at an international oncology conference in Munich on Wednesday.
Insulin resistance assessed by homeostasis model assessment index (HOMA2-IR) correlates with the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection, according to a study published online in the Journal of Gastroenterology and Hepatology.